Achievements and Opportunities

Michel Goldman, MD, PhD
Executive Director
Innovative Medicines Initiative: Joining Forces in the Healthcare Sector

2 Billion Euro

1 Billion € Public Partnership
1 Billion € Private Partnership

IMI

Public

Private

EFPIA
A Typical IMI Consortium

Private Investment ‘n kind

EU Public Funding cash
IMI Executive Office as a Neutral Third-Party

- Ensures that projects are carried out in the common interest of all stakeholders
- Guarantees fair conditions for knowledge exploitation and dissemination
- Facilitates the dialog between industry, patients’ organizations and regulatory agencies
## Calls 1 & 2: Consolidated Figures

<table>
<thead>
<tr>
<th>Category</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Projects (N)</td>
<td>23</td>
</tr>
<tr>
<td>EFPIA Companies (N)</td>
<td>23</td>
</tr>
<tr>
<td>Academic teams (N)</td>
<td>298</td>
</tr>
<tr>
<td>SME teams (N)</td>
<td>47</td>
</tr>
<tr>
<td>Patients’ organizations (N)</td>
<td>11</td>
</tr>
<tr>
<td>Regulatory agencies (N)</td>
<td>6</td>
</tr>
<tr>
<td>Budget (M€)</td>
<td>453</td>
</tr>
</tbody>
</table>
Develops biomarkers and tools and models to allow better targeted treatments for schizophrenia and depression

19 Partners
- 9 EFPIA companies
- 7 Public organisations
- 3 SMEs

First achievements

- Has assembled the largest known repository of antipsychotic clinical trial data.
- The database contains information on 23,401 patients from 67 industry sponsored studies.
- Bringing together data from public projects and 3 companies on the genetics and clinical response in 1,800 well characterized patients with depression.
U-BIOPRED

Paves the way towards a new classification of asthma and personalized treatments for patients

38 Partners
- 9 EFPIA companies
- 23 Academic institutions
- 3 Patients’ organizations
- 3 SMEs

First achievements
✓ A new stepwise algorithm for the stratification of patients with severe asthma

Thorax, in press
PRO-ACTIVE
PRO-ACTIVE

Activity Monitor
Amount of activities

PDA for E-PRO
Symptoms / other dimensions

Symptoms
Adaptations / PA

Time (days)
Addresses the current lack of sensitive and specific clinical tests to diagnose and monitor drug-induced injury to the kidney, liver and vascular tissues in man, which is a major hurdle in drug development.

20 Partners
- 11 EFPIA Pharma Companies
- 5 Academic Institutions
- 4 SMEs

First achievements

- 153 potential biomarker candidates for drug-induced injury of the kidney, liver and vascular system have been evaluated and are currently undergoing clinical evaluation.
- The strategy adopted has been agreed with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Builds a large searchable database containing drug toxicity-related data extracted from relevant pharmaceutical pre-clinical legacy reports. Develops innovative methodological strategies and novel software tools to better predict in silico the toxicological profiles of new molecular entities in early stages of the drug development pipeline, using its database background.

**25 Partners**
- 13 EFPIA companies
- 8 Public organisations
- 4 SMEs

**First achievements**
✓ An innovative multi-scale modelling strategy for the prediction of cardiotoxicity has been developed, successfully tested and published.

IMI Education & Training Programmes

- First course in Nov 2010 on drug discovery development
- Certificate and Master courses in pharmacovigilance and pharmacoepidemiology in Sept 2011
- EU syllabus on pharmaceutical medicine
- Database on over 700 master courses, 110 professional development courses, 380 learning tools

IMI EDUCATION AND TRAINING PROGRAMMES
Projects under elaboration (3rd Call)

- Early prediction of drug-induced liver injury
- Risk minimization of antibodies to biopharmaceuticals
- Immunosafety of vaccines
- Translational research on autism spectrum disorders
- Personalized medicine in type II diabetes
- New strategies to treat tuberculosis
- Patient awareness on pharmaceutical innovation
A Multidimensional Mission

THANK YOU!

www.imi.europa.eu